Author: Woods, Niamh; MacLoughlin, Ronan
Title: Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease Cord-id: 2nqm0tfl Document date: 2020_9_26
ID: 2nqm0tfl
Snippet: Advanced Therapeutic Medicinal Products (ATMP) are a heterogenous group of investigational medicinal products at the forefront of innovative therapies with direct applicability in respiratory diseases. ATMPs include, but are not limited to, stem cells, their secretome, or extracellular vesicles, and each have shown some potential when delivered topically within the lung. This review focuses on that subset of ATMPs. One key mode of delivery that has enabling potential in ATMP validation is aeroso
Document: Advanced Therapeutic Medicinal Products (ATMP) are a heterogenous group of investigational medicinal products at the forefront of innovative therapies with direct applicability in respiratory diseases. ATMPs include, but are not limited to, stem cells, their secretome, or extracellular vesicles, and each have shown some potential when delivered topically within the lung. This review focuses on that subset of ATMPs. One key mode of delivery that has enabling potential in ATMP validation is aerosol-mediated delivery. The selection of the most appropriate aerosol generator technology is influenced by several key factors, including formulation, patient type, patient intervention, and healthcare economics. The aerosol-mediated delivery of ATMPs has shown promise for the treatment of both chronic and acute respiratory disease in pre-clinical and clinical trials; however, in order for these ATMP device combinations to translate from the bench through to commercialization, they must meet the requirements set out by the various global regulatory bodies. In this review, we detail the potential for ATMP utility in the lungs and propose the nebulization of ATMPs as a viable route of administration in certain circumstances. Further, we provide insight to the current regulatory guidance for nascent ATMP device combination product development within the EU and US.
Search related documents:
Co phrase search for related documents- abnormal differentiation and acute respiratory disease: 1
- acid sequence and acute respiratory disease: 1, 2, 3, 4, 5, 6, 7, 8
- action site and administration route: 1, 2, 3
- action site and local concentration: 1, 2
- activation proliferation and acute ards respiratory distress syndrome: 1, 2
- activation proliferation and acute chronic: 1, 2
- activation proliferation and acute respiratory disease: 1, 2, 3
- activation proliferation and local tissue: 1
- acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and administration route dose: 1
- acute ards respiratory distress syndrome and local tissue: 1, 2, 3
- acute chronic and administration route: 1
- acute chronic and local tissue: 1, 2, 3
- acute respiratory disease and administration route: 1, 2
- acute respiratory disease and local tissue: 1, 2
- administration route and local tissue: 1
Co phrase search for related documents, hyperlinks ordered by date